연구성과로 돌아가기
2024 연구성과별 연구자 정보 (1471 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| mQUIC: Use of QUIC for Handover Support with Connection Migration in Wireless/Mobile Networks | Koh, Seok-Joo | Koh, SJ | 2 | Kyungpook Natl Univ, Daegu, South Korea | smalldragon024@gmail.com;sjkoh@knu.ac.kr; | |||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Sangro, B. | Sangro, B | 1 | Clin Univ Navarra, Liver Unit, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Sangro, B. | Sangro, B | 1 | Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Sangro, B. | Sangro, B | 1 | CIBEREHD, Pamplona, Spain | AFW-4106-2022 | Sangro, Bruno | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Kudo, M. | Kudo, M | 2 | Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan | AAA-9744-2019 | Kudo, Masatoshi | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Erinjeri, J. P. | Erinjeri, JP | 3 | Mem Sloan Kettering Canc Ctr, lntervent Radiol Serv, New York, NY USA | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Qin, S. | Qin, S | 4 | Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Ren, Z. | Ren, Z | 5 | Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Chan, S. | Chan, S | 6 | Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Translat Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Arai, Y. | Arai, Y | 7 | Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Heo, J. | Heo, J | 8 | Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea | MHQ-1390-2025 | Heo, Jeong | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Heo, J. | Heo, J | 8 | Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea | MHQ-1390-2025 | Heo, Jeong | ||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Mai, A. | Mai, A | 9 | Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Penagos, F. E. | Penagos, FE | 10 | Hosp San Lucas Cardiol Sureste, Chiapas, Mexico | ||||||
| mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | Chuken, Y. A. Lopez | Chuken, YAL | 11 | I Can Oncol Ctr, New Leon, Mexico |
페이지 이동: